ObjectiveCost-utility analyses are becoming increasingly important in Central and Eastern Europe. We aimed to develop a Polish utility tariff for EQ-5D-5L health states.MethodsFace-to-face, computer-assisted interviews were collected in a representative sample. Each respondent followed a standardised protocol to collect ten composite time trade-off and seven discrete choice experiment observations. In the Bayesian approach, several model specifications were compared based on model fit, the usability of the final value set and how they reflect the elicitation procedure (e.g. censoring). A hybrid approach (using composite time trade-off and discrete choice experiment data) was employed in the final set, which was compared with the existing ones: EQ-5D-3L and EQ-5D-5L cross-walk.ResultsData from 1252 respondents (11,480 composite time trade-off valuations and 8764 discrete choice experiment pairs) were collected over the period June to October 2016. The final model accounted for random parameters, error scaling with fat tails, censoring at − 1, unwillingness to trade in time trade-off by the religious people and Cauchy distribution in discrete choice experiments. Pain/discomfort impacts the utility most: the disutility equals 0.575 when at level 5. In the value set, 4.4% of EQ-5D-5L states are worse than dead. The new value set has a comparable range (minimum of − 0.590 compared to − 0.523) and the same ordering of the first three dimensions (pain/discomfort, mobility, self-care) as the EQ-5D-3L value set and the EQ-5D-5L cross-walk value set. Moreover, it is more sensitive to a moderate decline in health.ConclusionsThe new value set supports consistency with past decisions in cost-utility studies, while offering a better assessment of even moderate improvements in health. It could represent an option for Central and Eastern Europe countries lacking their own value sets.Electronic supplementary materialThe online version of this article (10.1007/s40273-019-00811-7) contains supplementary material, which is available to authorized users.

0 1 7 ) A 3 9 9 -A 8 1 1 female with CKD/HF, non-smoker, aged 60, eGFR 50 ml/min/1.73m2, serum potassium (K+) 4.5 mEq/L, without diabetes or renin-angiotensin-aldosterone system inhibitor (RAASi) prescription. Results were expressed as percentage increase/ decrease from baseline. Results: The listed characteristics were all statistically significant predictors of mortality. Baseline annual mortaility probability was 0.016 and 0.068 in males and 0.008 and 0.055 in females, with CKD and HF, respectively. RAASi use was associated with decreased probability of death compared to baseline in CKD (56.6%) and HF (69.3%). Older age, increased K+, diabetes, smoking and reductions in eGFR all increased estimated probability of death. The influence of eGFR was greater for CKD patients (36.4%-153% for 10-30 ml/min/1.73m2 reduction) compared to HF (18.4%-65.2% for 10-30 ml/min/1.73m2 reduction). While the impact of K+ was greater for HF: 7.2% and 58.4% for K+ 5.5 and 6.5 mEqL, respectively, compared to 2.1% and 24.9% for CKD. ConClusions: Utilising real-world UK data, this evaluation of the impact of clinical risk factors on mortality risk in patients with CKD or HF serves as the structural framework for a broader tool to enhance the assessment of risk of outcomes in patients susceptible to HK.